Pharmacokinetics and Pharmacodynamics of Platelet P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention (PCI) for Acute Myocardial Infarction: A Pilot Study - P3-AMI Antiplatelet Trial

The Royal Wolverhampton NHS Trust0 个研究点目标入组 87 人开始时间: 2015年1月13日最近更新: 2020年7月20日

试验速览

暂无简介。

•1)Patients presenting with STEMI for PCI (characterized by chest discomfort, and prominent ST-segment elevation)
•2)Patients presenting with NSTEMI (characterized by chest discomfort, raised levels of myocardial enzymes and/or ST-segment depression or prominent T wave inversion)
•3)Able to give verbal consent (STEMI patients pre procedure) and/or written consent (STEMI after procedure and NSTEMI patients prior to enrolment).
•4)Age>18 years of age
•5)Able to take Aspirin and either prasugrel or ticagrelor.
•6)Have no concurrent septic or inflammatory illness
•7)Thienopyridine naive
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 25
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•1)Be unable to provide verbal and written consent
•2)Allergic to aspirin or any of the P2Y12 antagonists in the trial
•3)Have pre-existing cardiogenic shock
•4)Have a concurrent septic or inflammatory disease e.g. rheumatoid arthritis, lupus, pneumonia.
•5)Already taking a P2Y12 inhibitor
•6)Known bleeding diathesis
•7)Patients under 75 years of age or under 60 kg or those who have had a previous stroke/transient ischaemic attack, will not be eligible for prasugrel but rather ticagrelor.
•8)Patients with a history of intracranial haemorrhage will not receive prasugrel or ticagrelor but rather will receive treatment with clopidogrel.

发起方